JP2017512194A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512194A5
JP2017512194A5 JP2016553329A JP2016553329A JP2017512194A5 JP 2017512194 A5 JP2017512194 A5 JP 2017512194A5 JP 2016553329 A JP2016553329 A JP 2016553329A JP 2016553329 A JP2016553329 A JP 2016553329A JP 2017512194 A5 JP2017512194 A5 JP 2017512194A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
fgf
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512194A (ja
JP6431083B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053624 external-priority patent/WO2015124727A1/en
Publication of JP2017512194A publication Critical patent/JP2017512194A/ja
Publication of JP2017512194A5 publication Critical patent/JP2017512194A5/ja
Application granted granted Critical
Publication of JP6431083B2 publication Critical patent/JP6431083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553329A 2014-02-20 2015-02-20 Fgf−18化合物の投与計画 Active JP6431083B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600.8 2014-02-20
EP14000600 2014-02-20
PCT/EP2015/053624 WO2015124727A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (3)

Publication Number Publication Date
JP2017512194A JP2017512194A (ja) 2017-05-18
JP2017512194A5 true JP2017512194A5 (show.php) 2018-03-08
JP6431083B2 JP6431083B2 (ja) 2018-11-28

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Country Status (25)

Country Link
US (2) US9889179B2 (show.php)
EP (2) EP3119417B1 (show.php)
JP (2) JP6431083B2 (show.php)
KR (2) KR102410986B1 (show.php)
CN (2) CN106232622A (show.php)
AR (2) AR099510A1 (show.php)
AU (2) AU2015220777B2 (show.php)
BR (2) BR112016018685A2 (show.php)
CA (2) CA2938791A1 (show.php)
DK (2) DK3107559T3 (show.php)
ES (2) ES2688551T3 (show.php)
HR (2) HRP20181570T1 (show.php)
HU (1) HUE040350T2 (show.php)
IL (2) IL247084B (show.php)
LT (2) LT3107559T (show.php)
MX (2) MX2016010872A (show.php)
NZ (1) NZ723148A (show.php)
PL (2) PL3107559T3 (show.php)
PT (2) PT3107559T (show.php)
RS (2) RS57853B1 (show.php)
RU (2) RU2691946C2 (show.php)
SG (2) SG11201606502YA (show.php)
SI (2) SI3107559T1 (show.php)
WO (2) WO2015124727A1 (show.php)
ZA (2) ZA201605547B (show.php)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086112B2 (en) 2014-02-20 2018-10-02 Merck Patent Gmbh Implant comprising FGF-18
CA2938791A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Fgf-18 compound dosing regimen
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
RU2743075C2 (ru) 2016-02-22 2021-02-15 Новартис Аг Способы применения агонистов fxr
HUE058786T2 (hu) 2017-09-29 2022-09-28 Merck Patent Gmbh FGF-18 vegyületre vonatkozó válaszkészség elõrejelzésére szolgáló metabolikus biomarkerek
DK3688468T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Inflammatoriske biomarkører til forudsigelse af modtageligheden for fgf-18 forbindelse
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
CA3127729A1 (en) * 2019-02-08 2020-08-13 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279835B2 (en) * 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
US20060009389A1 (en) * 2004-07-06 2006-01-12 Moore Emma E Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
KR101419961B1 (ko) * 2006-08-25 2014-07-30 아레스 트레이딩 에스.에이. Fgf-18 로 연골 질환의 치료
CN101505787B (zh) * 2006-08-25 2013-09-04 阿雷斯贸易股份有限公司 软骨障碍的治疗
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
CA2830882C (en) * 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
EP3107591B1 (en) 2014-02-20 2018-04-18 Merck Patent GmbH Fgf-18 in graft transplantation and tissue engineering procedures
US10086112B2 (en) 2014-02-20 2018-10-02 Merck Patent Gmbh Implant comprising FGF-18
CA2938791A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Fgf-18 compound dosing regimen

Similar Documents

Publication Publication Date Title
JP2017512194A5 (show.php)
JP2017507142A5 (show.php)
JP2012193216A5 (show.php)
JP2015517488A5 (show.php)
JP2015038135A5 (show.php)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2015057451A5 (show.php)
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
JP2016530280A5 (show.php)
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
RU2016137289A (ru) Схема применения соединения fgf-18
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2013541583A5 (show.php)
JP2017501140A5 (show.php)
JP2017503014A5 (show.php)
JP2016505050A5 (show.php)
JP2016512247A5 (show.php)
JP2018506533A5 (show.php)
JP2021505669A5 (show.php)
JP2017061488A5 (show.php)
JP2017531042A5 (show.php)
HRP20161796T1 (hr) Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice